Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose
Orexo AB announces the submission of a New Drug Application (NDA) to the US Food and […]
Abbott Announces US and European Approvals for New Technologies to Support Effective Treatment for Abnormal Heart Rhythms
Abbott has announced two approvals as part of its growing suite of electrophysiology products in […]
RefleXion Receives FDA Clearance for Biology-Guided Radiotherapy Treatment for Early and Late-stage Cancers
RefleXion Medical, a therapeutic oncology company, today announced the US Food and Drug Administration (FDA) […]
Cardiff Oncology Announces the Appointment of Fairooz Kabbinavar, MD, FACP, as Chief Medical Officer
Cardiff Oncology, a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to […]
iCRYO Announces Partnership with Therapeutic Manufacturer, BTL
iCRYO, the fast-growing recovery and wellness brand that focuses on a series of health-related recovery […]
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MMP7 for Treatment of Idiopathic Pulmonary Fibrosis
Arrowhead Pharmaceuticals announced today that it has dosed the first subjects in a Phase 1/2a […]
Agomab Reports Positive Phase 1 Results with AGMB-129, a GI-restricted ALK5 Inhibitor for Fibrostenosing Crohn’s Disease
Agomab Therapeutics today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an […]
Poseida Therapeutics Announces Board Change
Poseida Therapeutics, a clinical-stage cell and gene therapy company advancing a new class of treatments […]
Digital Diagnostics and Tamer Healthcare Announce Strategic Partnership in the Kingdom of Saudi Arabia
Digital Diagnostics, maker of IDx-DR, the first-ever FDA-cleared, fully autonomous AI system for the diagnosis […]
20Med Therapeutics and CEPI Sign Agreement to Advance ThermoStable Vaccines Technology
20Med Therapeutics, a leader in non-viral delivery of genetic vaccines using polymeric nanoparticles, and CEPI, […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more